BD BBL™ Sensi-Disc™ Ceftazidime 30 µg 231633Recalls & reported problems
Becton, Dickinson And Company · BD BBL™ Sensi-Disc™ Ceftazidime 30 µg · Class 2
All models of BD BBL Sensi-Disc Ceftazidime - 30 µg (2)
Data updated Oct 18, 2026 from official FDA records · Editorial policy
1 open recall names this device. See the recall details and contact the manufacturer or your healthcare provider.
- Adverse event reports
- 1
- Deaths reported
- 0
- Injuries reported
- 0
- Recalls naming it
- 1
Summary
The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 30382902316337), received between May 9, 2025 and May 9, 2025 — classified as 1 malfunction.
The most frequently reported specific device problem is “Device Markings/Labelling Problem” (1 report).
1 FDA recall record name this device's identifier, 1 still open.
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Reports received per month
Recalls naming this device
- Jan 8, 2024Class IIOpen, Classified
There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.
Z-1023-2024 · Root cause: Process control · Recall details · FDA record ↗
Most reported problems
Device problems
- Device Markings/Labelling Problem1
Patient problems
- No Clinical Signs, Symptoms or Conditions1
Recent adverse event reports
The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.
MalfunctionMay 9, 2025Device Markings/Labelling Problem; Device Markings/Labelling Problem
IT WAS REPORTED PRIOR TO USING THE BD BBL¿ SENSI-DISC¿ CEFTAZIDIME 30 ¿G, THE USER NOTED THAT THE LABEL OF THE CARTRIDGE CONTAINING THE PRODUCT (INTERNAL LABELING) WAS DIFFERENT FROM THE SHELF PACKAGE LABEL (EXTERNAL LABEL). NO HEALTH IMPACT OR CONSEQUENCE REPORTED.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 21997189 ↗
Other SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL devices
- BD BBL Sensi-Disc Ampicillin 2 ug 231263Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL2 recalls0 reports
- BD BBL™ Sensi-Disc™ Ciprofloxacin 5 µg 231658Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall2 reports
- BD BBL™ Sensi-Disc™ Piperacillin/Tazobactam 100/10 µg 231691Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall1 report
- BD BBL™ Sensi-Disc™ Levofloxacin 5 µg 231706Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall1 report
- BD BBL™ Sensi-Disc™ Cefepime 30 µg 231696Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall1 report
- BD BBL™ Sensi-Disc™ Chloramphenicol 30 µg 231274Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall0 reports
- BD BBL™ Sensi-Disc™ Cefotaxime 30 µg 231607Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall0 reports
- BD BBL™ Sensi-Disc™ Chloramphenicol - 30 µg 230733Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall0 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026 · each recall links to the FDA recall notice
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page